VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and ...

Q4 2025 . Management View. Curran Simpson, President and CEO, stated, "2026 is set to be a pivotal year for REGENXBIO with great focu ...

Q4 2025 Management View Jay Duker, President and CEO, stated that “2025 was defined by significant progress and achievement for EyePoint as we made important advances that set the stage for success ...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational ...

A single injection of the tyrosine kinase inhibitor hydrogel has demonstrated superiority to aflibercept 2 mg in maintaining visual acuity and providing higher rescue-free rates through 1 year in ...

Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 –– Patients dosed in both COMO and ...

The Agency is now requiring the submission of confirmatory efficacy data to support the application. The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Outlook ...

Please provide your email address to receive an email when new articles are posted on . EYP-1901 and OTX-TKI have shown results similar to aflibercept 2 mg. Gene therapy is another type of treatment ...

This is a quickly progressing field, according to Sarju Patel, MD, attending physician at Retinal Consultants of America. He has high expectations that advances from subtly tinted eyeglass lenses to ...